With the Pharmaceutical Price Regulation Scheme (PPRS) being renegotiated, Leela Barham looks at the trends in National Institute for Health and Care Excellence (NICE) recommendations and asks
Jeremy Smith discusses the cost:benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them while still
In Deep Dive: Market Access II, Eric Low shares his views on why hurdles remain to new drug access – and how medical research charities can lead the way in multi-stakeholder research collaborat
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho
